TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Problems
Premature ovarian insufficiency
Key Statistics
- <40 yrs — Age cut-off (2 SD below 50±4)
- 1% — Prevalence in women <40
- >25 IU/l — ESHRE FSH threshold ×2, >4 WKS apart
Don't-miss facts
-
POI = oligo-/amenorrhoea ≥4 months + FSH >25 IU/l on 2 occasions ≥4 weeks apart, aged <40 (ESHRE)
-
Karyotype in every non-iatrogenic case regardless of age; FMR1 premutation testing only after counselling (family implications; male carriers → FXTAS)
-
Autoimmune screen: ACA + 21OH-Ab + TPO-Ab; TPO-Ab positive → annual TSH. DEXA at diagnosis
-
Continue HRT to age 50–51; target estradiol 180–370 pmol/l = 50–100 mcg patch or 2–4 mg oral daily
-
Uterus present → add progestogen (continuous 100 mg micronised / MPA 2.5–5 mg / NET 1 mg; sequential 200 mg or MPA 10 mg ≥12 days/month). No uterus → estrogen only
-
HRT is not contraception — spontaneous pregnancy in 5–10%; exclude pregnancy before/during workup
-
Transdermal preferred in smokers, migraine, hypertension, VTE risk. COCP not recommended in migraine with aura; HRT not recommended after breast cancer (use gabapentin/venlafaxine/fluoxetine)
-
Fertility = donor-oocyte IVF (high-risk pregnancy, hospital antenatal care). Cryopreservation has no role in established POI. GnRH agonist during chemotherapy reduces POI incidence
Red flags & must-not-miss
XY gonadal dysgenesis → 45% gonadal neoplasia risk — consider gonadectomy 21OH-Ab positive → latent Addison’s disease
Puberty induction: estrogen from age ≥12, progestogen delayed ≥2 years
Support: The Daisy Network · Turner Syndrome Support Society
Abbreviation Key
- POI — premature ovarian insufficiency
- BMD / DEXA — bone mineral density / dual-energy x-ray absorptiometry
- ESHRE — European Society of Human Reproduction and
- Embryology SCA / ACA — steroid cell / adrenocortical antibodies
- BMS / NICE — British Menopause Society / National Institute for
- 21OH-Ab / TPO-Ab — 21-hydroxylase / thyroid peroxidase Health and Care Excellence autoantibodies
- FSH / LH / AMH — follicle-stimulating / luteinising hormone; anti- FMR1 /
- FXPOI / FXTAS — Fragile-X mental retardation 1 gene / Müllerian hormone Fragile-X-associated POI / Fragile-X-associated tremor-ataxia syndrome
- HRT / COCP — hormone replacement therapy / combined oral
- contraceptive pill VTE / GnRH — venous thromboembolism / gonadotrophin-releasing hormone
- CEE / MPA — conjugated equine estrogen / medroxyprogesterone acetate
Source: Sayed H, Jayaprakasan K. Premature ovarian insufficiency. The Obstetrician & Gynaecologist 2024;26:152–162. doi:10.1111/tog.12943
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).